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Abstract
Background: Posttraumatic stress disorder is an anxiety disorder characterized by deficits in the extinction of aversive 
memories. Insulin-like growth factor 1 (IGF1) is the only growth factor that has shown anxiolytic and antidepressant 
properties in human clinical trials. In animal studies, insulin-like growth factor binding protein 2 (IGFBP2) shows both IGF1-
dependent and IGF1-independent pharmacological effects, and IGFBP2 expression is upregulated by rough-and-tumble play 
that induces resilience to stress.
Methods: IGFBP2 was evaluated in Porsolt, contextual fear conditioning, and chronic unpredictable stress models of 
posttraumatic stress disorder. The dependence of IGFBP2 effects on IGF1- and AMPA-receptor activation was tested using 
selective receptor antagonists. Dendritic spine morphology was measured in the dentate gyrus and the medial prefrontal 
cortex 24 hours after in vivo dosing.
Results: IGFBP2 was 100 times more potent than IGF1 in the Porsolt test. Unlike IGF1, effects of IGFBP2 were not blocked by the 
IGF1-receptor antagonist JB1, or by the AMPA-receptor antagonist 2,3-Dioxo-6-nitro-1,2,3,4 tetrahydrobenzo[f]quinoxaline-7-
sulfonamide (NBQX) in the Porsolt test. IGFBP2 (1 µg/kg) and IGF1 (100 µg/kg i.v.) each facilitated contextual fear extinction and 
consolidation. Using a chronic unpredictable stress paradigm, IGFBP2 reversed stress-induced effects in the Porsolt, novelty-
induced hypophagia, sucrose preference, and ultrasonic vocalization assays. IGFBP2  also increased mature dendritic spine 
densities in the medial prefrontal cortex and hippocampus 24 hours postdosing.
Conclusions: These data suggest that IGFBP2 has therapeutic-like effects in multiple rat models of posttraumatic stress 
disorder via a novel IGF1 receptor-independent mechanism. These data also suggest that the long-lasting effects of IGFBP2 
may be due to facilitation of structural plasticity at the dendritic spine level. IGFBP2 and mimetics may have therapeutic 
potential for the treatment of posttraumatic stress disorder.
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Introduction
Posttraumatic stress disorder (PTSD) is a major anxiety disor-
der that is characterized by deficits in the extinction of fearful 
memories. PTSD affects as many as 30% of individuals that have 
been directly associated with psychologically traumatic events 
(Breslau et al., 1998). PTSD is considered a memory disorder in 
which cues associated with the traumatic event form power-
ful sensory memories that are resistant to extinction (Parsons 
and Ressler, 2013). Serotonin specific reuptake inhibitors (SSRIs) 
are widely used to treat PTSD but with limited efficacy (Ipser et 
al., 2015), thus there is a great unmet need for the treatment of 
PTSD.
Growth factor receptor activation has been suggested to 
have potential for treatment of PTSD (Duman and Monteggia, 
2006; Soliman et al., 2010). Insulin-like growth factor I (IGF1) has 
been approved by the FDA for human use in congenital dwarf-
ism (NDA21-839) and has been reported to have both anxio-
lytic and antidepressant effects in humans when injected i.p. 
(Thompson et al., 1998). IGF1 plasma levels are positively corre-
lated with decreased expression of PTSD symptoms in humans 
(Rusch et al., 2015). In addition, IGF1, brain derived neurotrophic 
factor, and fibroblast growth factor have all been shown to be 
decreased in depressed patients and elevated by treatment with 
conventional antidepressants (Duman and Monteggia, 2006; Sen 
et al., 2008).
Insulin-like growth factor binding protein 2 (IGFBP2) may 
have therapeutic potential for the treatment of PTSD. IGFBP2 is 
the predominant IGF1 binding protein in the brain and cerebro-
spinal fluid, is present at low levels in the periphery (Ocrant et 
al., 1990; Poljakovic et al., 2006), and has been shown to cross the 
blood-brain barrier (Huhtala et al., 2012). IGFBP2 has a molecu-
lar weight of 36 kD and has multiple biological effects, some of 
which are independent of its binding to IGF1, mediated by differ-
ent binding domains within IGFBP2 (Firth and Baxter, 2002; Azar 
et al., 2014; Reyer et al., 2015). Rough-and-tumble play robustly 
induces resilience to stress (Burgdorf et al., 2016) and upregu-
lates IGFBP2 mRNA and protein levels in the medial prefrontal 
cortex (Burgdorf et al., 2010).
PTSD can be modeled in rodents by measuring emotional 
responses to stress and extinction of these behaviors. Key 
symptoms of PTSD in humans are persistent recurrent thoughts 
of traumatic events, especially when reexposed to cues, 
and increased anxiety and depressive symptoms (American 
Psychiatric Association, 2013). In rodents, fear extinction tasks 
can model the persistence of cue-induced stress responses, 
whereas repeated stress can model the anxiety and depres-
sion symptoms of PTSD (Burgdorf et al., 2015b). In these stress 
models, increases in negative affect are measured by the Porsolt 
and novelty-induced hypophagia tests, and decreases in posi-
tive affect/anhedonia are measured by the sucrose preference 
test. In addition, the ultrasonic vocalization test measures both 
negative (20-kHz ultrasonic vocalization [USVs]) and positive 
affect (50-kHz USVs).
Chronic unpredictable stress (CUS) can be used to test for 
rapid-acting therapeutics for PTSD. CUS induces a long-lasting 
and robust PTSD-like phenotype that models clinical features 
of PTSD and has been well characterized at the behavio-
ral, physiological, cellular, and molecular levels (Duman and 
Aghajanian, 2012; Burgdorf et al., 2015b). CUS induces a behav-
ioral phenotype that is responsive to chronic (3 weeks) but not 
acute or short-term treatment with fluoxetine (Schmidt and 
Duman, 2007) and is sensitive to rapid-acting therapeutics (Li 
et al., 2010; Burgdorf et al., 2013). Thus, the CUS model provides 
a rigorous paradigm for identifying compounds with rapid-act-
ing therapeutic efficacy in PTSD, thereby differentiating IGF1 
and IGFBP2 from the currently approved therapeutics for this 
disorder.
The experiments in this study tested whether IGFBP2 has 
therapeutic potential for the treatment of PTSD by using a con-
textual fear conditioning paradigm to measure extinction and 
consolidation and a CUS paradigm to measure anxiety and 
depressive-like symptoms of PTSD. IGFBP2 was chosen because 
of its role in resilience to stress induced by positive affect 
(Burgdorf et al., 2010). Since the behavioral effects of IGF1 are 
known to be IGF1 and AMPA receptor dependent, we determined 
whether the behavioral effects of IGFBP2 were also IGFIR and 
AMPAR dependent. Finally, we performed dendritic spine analy-
sis in the medial prefrontal cortex and hippocampus 24 hours 
after dosing to determine whether changes in structural plastic-
ity were associated with the long-lasting behavioral effects of 
IGFBP2.
Materials and Methods
Animals
Adult male 2- to 3-month-old Sprague-Dawley (SD) rats from 
Envigo Inc. were used. Rats were housed in Lucite cages with 
aspen wood chip bedding, maintained on a 12:12 light:dark cycle 
(lights on at 5 am), and given ad libitum access to Purina lab 
chow and tap water throughout the study. All experiments were 
approved by the Northwestern University Institutional Animal 
Care and Use Committees.
Drugs
IGFBP2 was purchased from PeproTech, IGF1 was purchased 
from Shenandoah Biotechnology, the IGF1 antagonist JB1 was 
purchased from Sigma, and the AMPA/kainate receptor antago-
nist 2,3-Dioxo-6-nitro-1,2,3,4 tetrahydrobenzo[f]quinoxaline-
7-sulfonamide (NBQX) disodium salt was purchased from 
Significance Statement
IGFBP2 has therapeutic potential for the treatment of PTSD and appears to produces its therapeutic-like effects by facilitating 
brain plasticity.
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Abcam. Doses for IGF1 and IGFBP2 were determined by dose 
response studies (Figure  1), and doses of JB1 and NBQX were 
chosen from Burgdorf et al. (2015a). All drugs were administered 
in sterile saline vehicle at a volume of 1 mL/kg.
Porsolt Test
Testing was conducted as described in Burgdorf et  al. (2013, 
2015a). Animals were placed in a 46-cm-tall x 20-cm-diameter 
clear glass tube filled to 30 cm with tap water (23 ± 1°C) for 15 
minutes on the first day (habituation) and 5 minutes on the sub-
sequent test days at 1 hour postdosing for non-CUS-treated rats, 
or during the last 5 minutes of the habituation trial for CUS-
treated rats 1 hour after dosing or 24 hours after the last rough-
and-tumble play session. Water was changed after every other 
animal. Animals were videotaped. Immobility time was defined 
as the minimal amount of effort required to keep the animals 
head above water. Experiments were conducted in a blind man-
ner and scored offline by an experimenter with high inter-rater 
reliability (Pearson’s r > .9).
JB1 Studies
The day after Porsolt habituation, non-CUS rats were dosed with 
IGFBP2 (1 μg/kg i.v.), the IGF1R antagonist JB1 (0.5 mg/kg i.v.), co-
administration of both IGFBP2 and JB1, or sterile saline vehicle 
(1 mL/kg i.v.). All animals received a single 5-minute Porsolt test 
session 1 hour postdosing (n = 6–8/group).
NBQX Studies
The day after Porsolt habituation, non-CUS-treated rats were 
dosed with IGFBP2 (1 μg/kg i.v.) or sterile saline vehicle (1 mL/kg 
i.v.). NBQX (10 mg/kg i.p.) or sterile saline vehicle (1 mL/kg i.p.) 
was coadministered with IGFBP2 or vehicle. All animals received 
a single 5-minute Porsolt test session 1 hour after dosing (n = 8/
group).
Contextual Fear Extinction
Testing was conducted as previously described (Burgdorf et al., 
2015b), and the first extinction tests occurred 1 hour postdosing. 
On the contextual fear training day (D0), animals were placed in 
a Coulbourn Instruments shock chamber (40 × 40 × 40 cm) for 
400 seconds and received three 0.5-mA 1-s footshocks delivered 
to the floor bars at 90-, 210-, and 330-second timepoints. During 
extinction, rats were subjected to daily 5-minute nonreinforced 
(no shock) extinction trials for the first 6 days after training and 
on day 14 posttraining (consolidation trial). Freezing was quan-
tified via FreezeFrame software (Actimetrics) during the last 3 
minutes of each extinction trial. Animals were dosed with a sin-
gle optimal dose of IGFBP2 (1 µg/kg i.v.), IGF1 (100 µg/kg i.v.), or 
sterile saline vehicle (1 mL/kg i.v.) 1 hour before the first extinc-
tion session (n = 9–11/group).
CUS Procedures
Rats were exposed to a CUS protocol previously shown to elicit 
depression-like symptoms in rats (Li et al., 2011; Burgdorf et al., 
2015a). Animals received 21 days of CUS before dosing and con-
tinued to receive CUS until the animals were killed 1 day after 
the last behavioral test (total of 37 days of CUS). A total of 9 dif-
ferent CUS stressors were used (2 stressors/d). The stressors 
(days) included rotation on a shaker for 1 hour (3, 9, 13, 19, 24, 
28, 33, 37), placement in a 4°C ambient for 1 hour (1, 5, 12, 14, 
18, 22, 26, 30, 36), lights off for 3 hours from 10:00 am to 1:00 pm 
(2, 10, 17, 23, 31, 34, 37), lights on overnight (1, 5, 8, 13, 16, 22, 32, 
34), strobe light overnight (3, 6, 9, 14, 17, 20, 23, 28, 31, 33), 45° 
tilted cages overnight (4, 7, 11, 15, 18, 21, 25, 29, 35), food and 
water deprivation overnight (2, 6, 10, 15, 19, 26, 27, 30), crowded 
housing overnight (4, 7, 11, 16, 21, 25, 29, 35), and isolation hous-
ing overnight (8, 12, 20, 24, 27, 32, 36). Animals in the no-CUS 
group (n = 9) were weighed every 4 days and received behavioral 
testing without additional stressors. Animals in the CUS groups 
received a single optimal dose of IGFBP2 (1 μg/kg i.v.; n = 8) or 
sterile saline vehicle (n = 10).
Sucrose Preference Test
Testing was conducted as described in Li et al., 2011 and Burgdorf 
et al., 2015a, and testing occurred 3 days postdosing or after the 
last rough-and-tumble play session. Rats were exposed to a pal-
atable sucrose solution (1%; Sigma) for 48 hours, followed by 4 
hours of water deprivation and a 1-hour exposure to 2 identical 
bottles, one filled with sucrose solution and the other with tap 
water. Sucrose preference was defined as the ratio of the volume 
of sucrose vs total volume of sucrose and water consumed dur-
ing the 1-hour test.
Novelty-Induced Hypophagia (NIH) Test
Testing was conducted as described in Burgdorf et al., 2013, 
2015a, and testing occurred 2 days postdosing or after the last 
rough-and-tumble play session. Animals were food deprived 
on the night before testing, and lab chow was placed into the 
center chamber of the open field (40 x 40 x 20 cm) for 10 minutes 
under dim-red lighting. Between animals, feces and urine were 
removed from the apparatus. Immediately after NIH testing, 
the latency to eat in the animal’s home cage was determined 
Figure 1. A single i.v. dose of insulin-like growth factor binding protein 2 (IGFBP2) 
produces therapeutic-like effect in the Porsolt test with 100-fold greater potency 
than insulin-like growth factor I  (IGF1). Mean ± SEM immobility time in non-
chronic unpredictable stress (CUS)-exposed rats treated with a single injection 
of IGFBP2 (0.3 to 10 µg/kg i.v.), IGF1 (30–1000 µg/kg i.v.), or saline vehicle (1 mL/kg) 
and tested 1 hour postdosing. *P < .05 Fisher’s PLSD posthoc test vs vehicle. n = 7 
to 8/group. Data for IGF1 was adapted from Burgdorf et al. (2015a).
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as a control. Animals were videotaped and latency (in seconds) 
for the animal to take the first bite of food, as well as locomotor 
activity (in line crosses), was scored offline by an experimenter 
blinded to the treatment condition.
USV Test
Heterospecific rough-and-tumble play was conducted as pre-
viously described (Burgdorf et  al., 2013, 2015a), and testing 
occurred 3 hours and postdosing or 1 day after the last rough-
and-tumble play session. Heterospecific rough-and-tumble play 
stimulation was administered by the experimenter’s right hand. 
The experimenter was blind to the treatment condition of the 
animals. Animals received 3 minutes of heterospecific rough-
and-tumble play consisting of alternating 15-second blocks of 
heterospecific play and 15 seconds of no-stimulation. High-
frequency USVs were recorded and analyzed by sonogram in 
a blind manner as described previously (Burgdorf et al., 2011). 
Animals were not habituated to play stimulation before dos-
ing and testing. Using this paradigm, we have shown that the 
increase in 50-kHz USVs that occurs across trial blocks reflects 
positive emotional learning (Burgdorf et al., 2011).
Dendritic Spine Morphology Analysis
Dendritic spine analyses were conducted as described in 
Burgdorf et al., 2015c. Animals were dosed with a single dose 
of IGFBP2 (1 µg/kg i.v.), IGF1 (100 µg/kg i.v.), or 0.9% sterile 
saline vehicle (1 mL/kg), and 24 hours postdosing they were 
deeply anesthetized (isoflurane) and brains fixed via cardiac 
perfusion using 4% paraformaldehyde. Brains were stored in 
ice cold 0.1 M phosphate buffer and stored at 4°C until sec-
tioning. Brains were sectioned using a tissue Vibratome (Leica 
VT1000) to collect sections (300 μm thick) from the anterior 
to posterior extremes of each brain. Ballistic dye labeling (DiI 
and DiO; 3 mg dissolved in methylene chloride and coated on 
tungsten particles) was performed using a commercially avail-
able gene gun (Bio-Rad, Hercules, CA) to label target neurons. 
Thick sections were mounted to slides with raised barriers 
using ProLong Gold (Life Technologies, Gaithersburg, MD) and 
cover slipped. Laser‐scanning confocal microscopy (Olympus 
FV1000) was performed using a 63× objective (1.42 NA) to scan 
individually labeled neurons at high resolution (0.103- × 0.103- 
× 0.33-μm voxels). Target neurons were identified in the brain 
regions of interest by anatomical location and cell morphology. 
Microscopy was performed blind to experimental conditions. A 
minimum of 5 cells per animal were sampled from each of the 
2 regions. For medial prefrontal cortex (MPFC), samples (50 μm) 
were collected from proximal tufts. Two positions from dentate 
granule neurons in the hippocampus were selected based on 
well-described discriminate connectivity between these lami-
nae (Llorens-Martín et al. 2014): (1) primary dendrites within 
the inner molecular layer, and (2) secondary dendrites from the 
middle molecular layer. For dentate granule neurons, samples 
(50 μm) were collected from primary dendrites starting at 100 
μm from the soma or the secondary dendrites 50 μm from the 
branch point.
Blind deconvolution (AutoQuant) was applied to raw 
3‐dimensional digital images that were then analyzed for spine 
density and morphology by trained analysts. Individual spines 
were measured manually for head diameter, spine length, and 
spine neck diameter from image Z-stacks using software cus-
tom-designed by Afraxis Inc. Each dendrite was analyzed by 3 to 
4 independent analysts. Automated image assignment software 
(C++) distributed images to analysts in a randomized man-
ner and ensured that each analyst performed measurements 
of near equal numbers of dendrites per group. Analysts were 
blinded to all experimental conditions (including treatment, 
brain region, and cell type). Statistical analysis of interanalyst 
variability for each dendrite was examined online and used to 
eliminate dendrites that did not meet interanalyst reliability 
criteria. For spine density and spine morphological classifica-
tion, data across analysts were averaged to report data for each 
dendrite. Identification, measurement, and classification of den-
dritic spines were performed as previously described (Ota et al., 
2014). For the purposes of the current study, we have denoted 
thin spines as “immature” to underscore their vulnerability 
to modification and role in recent encoding processes relative 
to more “mature” classes (i.e., mushroom and stubby classes), 
which are more closely associated with long-term memory 
storage (Young et al., 2014). Data population values (n’s) were 
reported for dendrites collected equally from all rats.
Statistical Analysis
Data were analyzed by ANOVA, followed by Fisher’s PLSD post-
hoc test (Statview). The level of statistical significance was set 
at P < .05.
Results
IGFBP2 Is 100 Times More Potent Than IGF1 in 
the Porsolt Test and Is IGF1- and AMPA-Receptor 
Independent
IGFBP2 (0.3 to 10  μg/kg i.v.) reduced immobility time in the 
Porsolt test 1 hour postdosing [F(4, 31) = 51.99, P < .05; Fisher’s 
PLSD posthoc test all IGFBP2 doses vs vehicle] (Figure 1). The low-
est maximally effective dose of IGFBP2 was 1 μg/kg i.v. [Fishers 
PLSD posthoc test 0.3 vs 10, P < .05; 0.3 vs all other IGFBP2 doses, 
P < .001]. However, unlike IGF1, the antidepressant-like effect 
of IGFBP2 was not blocked by coadministration of either JB1 or 
NBQX [F(3,32) = 129.17, P < .0001; Fisher’s PLSD posthoc test for 
vehicle vs all other treatments] (Figure 2).
A Single Dose of IGFBP2 or IGF1 Facilitated 
Contextual Fear Extinction and Consolidation
IGFBP2 (1 μg/kg iv) or IGF1 (100 μg/kg iv) facilitated contextual fear 
extinction as measured by reduced freezing time [F(2, 28) = 8.80, 
P < .05; Fisher’s PLSD posthoc test IGFBP2 or IGF1 vs vehicle from 
repeated-measures ANOVA analysis; P < .05; Fisher’s PLSD post-
hoc test IGFBP2 vs vehicle for D1-6 and D14, and IGF1 vs vehicle 
for D2-6 and D14 Fisher’s PLSD posthoc test on individual test 
days] (Figure 3A). IGFBP2 or IGF1 also facilitated contextual fear 
consolidation as measured by the change in freezing score from 
the last extinction day (D6) compared with the consolidation 
day 14 [F(2, 28) = 5.99, P < .05; Fisher’s PLSD posthoc test IGFBP2 
or IGF1 vs vehicle] (Figure 3B).
A Single i.v. Dose of IGFBP2 Produces a Rapid-Acting 
and Long-Lasting Therapeutic-Like Effect in a CUS 
Model of PTSD
IGFBP2 (1  μg/kg, i.v.) treatment in rats exposed to CUS sig-
nificantly reduced immobility time in the Porsolt test (1 hour 
postdosing) compared with CUS-treated vehicle rats, and CUS 
vehicle rats showed increased immobility times compared with 
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no-CUS-treated rats [F(2, 21)  =  63.61, P < .0001; Fisher’s PLSD 
posthoc test IGFBP2 vs vehicle, or vehicle vs no-CUS control, P < 
.0001] (Figure 4A). Furthermore, IGFBP2 increased sucrose pref-
erence scores in CUS-treated rats (4 days postdosing) compared 
with CUS-treated vehicle rats, while CUS vehicle-treated rats 
showed significantly decreased sucrose preference scores com-
pared with no-CUS-treated rats [F(2, 21) = 14.3, P = .0001; Fisher’s 
PLSD posthoc test IGFBP2 vs vehicle, P < .0001; vehicle vs no-CUS 
control, P < .01] (Figure 4B).
IGFBP2 also significantly decreased feeding latency in a novel 
environment in the NIH test (2 days postdosing) compared with 
CUS-treated vehicle rats, while CUS vehicle rats showed longer 
feeding latencies compared with no-CUS-treated rats [F(2, 
21) = 7.78, P < .01; Fisher’s PLSD posthoc test IGFBP2 vs vehicle, 
vehicle vs no-CUS control, P < .01], while no changes were seen 
in latency to eat in the homecage [F(2, 26) = 0.4, P > .05; data not 
shown] or line crosses in the novel environment [F(2, 26) = 0.3, 
P > .05; data not shown] (Figure 4C).
Finally, IGFBP2 increased weight gain (1 week postdosing) 
compared with CUS-treated vehicle rats, while CUS vehicle rats 
showed decreased weight gain compared with no-CUS-treated 
rats [F(2, 21) = 7.78, P < .01; Fisher’s PLSD posthoc test IGFBP2 vs 
vehicle, vehicle vs no-CUS control, P < .01] (Figure 4D).
IGFBP2 Reversed CUS-Induced Deficits in Positive 
Emotional Learning
IGFBP2 in CUS-treated rats increased rates of hedonic 50-kHz 
USVs in response to a temporal CS that predicted heterospecific 
play (positive emotional learning) compared with vehicle CUS-
treated rats, and CUS vehicle rats showed decreased CS-elicited 
hedonic 50-kHz USVs compared with no-CUS-treated rats [F(2, 
21) = 7.19, P < .01; Fisher’s PLSD posthoc test IGFBP2 vs vehicle, 
vehicle vs no-CUS control, P < .01] (Figure 4E). IGFBP2 in CUS-
treated rats increased rates of hedonic USVs (Figure  4F) and 
reduced rates of aversive 20  kHz (Figure  4G) compared with 
vehicle CUS-treated rats, while CUS vehicle-treated rats showed 
decreased hedonic 50-kHz USVs and increased aversive 20-kHz 
USVs compared with no-CUS-treated rats [hedonic USVs F(2, 
21) = 58.59, P < .0001; Fisher’s PLSD posthoc test IGFBP2 vs vehicle, 
vehicle vs no-CUS control, P < .0001; aversive USVs F(2, 21) = 8.29, 
P < .01 Fisher’s PLSD posthoc test IGFBP2 vs vehicle, vehicle vs 
Figure 2. The therapeutic-like effects of insulin-like growth factor I (IGF1), but not insulin-like growth factor binding protein 2 (IGFBP2), are IGF1R- and AMPA-receptor 
(AMPAR) dependent. (A) Mean ± SEM immobility time in non-chronic unpredictable stress (CUS)-exposed rats treated with a single i.v. injection of IGF1 (100 µg/kg), 
coadministration of IGF-1 and JB1 (0.5 mg/kg i.v.) or NBQX (10 mg/kg i.p.), or saline vehicle (1 mL/kg), and tested 1 hour postdosing. (B) Mean ± SEM immobility time 
in non-CUS-exposed rats treated with a single i.v. injection of IGFBP2 (1 µg/kg i.v.), coadministration of IGFBP2 and JB1 (0.5 mg/kg, i.v.), or 2,3-Dioxo-6-nitro-1,2,3,4 
tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX) (10 mg/kg, i.p.), or saline vehicle (1 mL/kg) and tested 1 hour postdosing. *P < .05 Fisher’s PLSD posthoc test vs 
vehicle. n = 6 to 9/group. Data for IGF1 were adapted from Burgdorf et al. (2015a).
Figure 3. A single dose of insulin-like growth factor binding protein 2 (IGFBP2) or insulin-like growth factor I (IGF1) facilitated contextual fear extinction and consolida-
tion. Mean ± SEM percent time freezing in animals dosed with IGFBP2 (1 µg/kg i.v.), IGF1 (100 µg/kg i.v.), or sterile saline vehicle (1 mL/kg i.v.) 1 hour before extinction 
day 1. Three shocks (0.5 mA, 1 s) were administered 90, 210, and 330 s after animals were placed in the conditioning chamber on D0. (A) During extinction, rats were 
submitted to a 5-minute nonreinforced test trial every 24 hours for 6 consecutive days (D1-6), and on day 14 postconditioning (the consolidation trial) and freezing was 
quantified via FreezeView software and was measured during the last 3 minutes of each trial. (B) Consolidation was measured by the increase in freezing behavior on 
the last extinction day compared with the consolidation day (D14-D6). n = 9–11 rats/group. *P < .05 Fisher’s PLSD posthoc test vs vehicle.
Downloaded from https://academic.oup.com/ijnp/article-abstract/20/6/476/2965640
by New York Medical College user
on 05 June 2018
Burgdorf et al. | 481
no-CUS control, P < .01]. As shown in Figure 4H, IGFBP2 in CUS-
treated rats also significantly increased running speed to self-
administer heterospecific play vehicle CUS-treated rats, while 
CUS vehicle rats showed decreased running speed compared 
with no-CUS-treated rats [F(2, 26) = 32.72, P < .0001; Fisher’s PLSD 
posthoc test IGFBP2 vs vehicle, vehicle vs no-CUS control, P < 
.0001].
In No-CUS Rats, IGFBP2 Was Active in the Porsolt, 
Sucrose Preference, NIH, and Positive Emotional 
Learning Tests, but Did Not Alter Body Weight
In no-CUS rats, IGFBP2 (n = 9) compared with vehicle (n = 9) 
reduced immobility time in the Porsolt test [F(1, 16) = 40.1, P 
< .0001; supplemental Figure 2A], increased sucrose prefer-
ence [F(1, 16) = 6.2, P < .05; supplemental Figure 2B], decreased 
feeding latency in the NIH test [F(1, 16) = 19.0, P < .001; sup-
plemental Figure 2C], increased positive emotional learning 
during the final 2 testing blocks [F(1, 16) = 10.5, P < .01; sup-
plemental Figure 2E], increased total hedonic USVs [F(1, 16) = 
59.0, P < .0001; supplemental Figure 2F], reduced total aversive 
USVs [F(1, 16) = 12.0, P < .001; supplemental Figure 2G], and 
increased the rewarding value of play as indexed by running 
speed [F(1, 16) = 6.9, P < .05; supplemental Figure 1H] but did not 
alter body weight gain 7 days postdosing [F(1, 16) = 1.6, P > .05; 
supplemental Figure 1D]. Although the vehicle non-CUS values 
appear to be closer to the vehicle CUS values of the previous 
experiment, they were within the range of non-CUS control 
values based on previous studies using these assays (Burgdorf 
et al., 2009, 2011, 2013).
IGFBP2 Increased Mature Spine Density in MPFC 
Layer V Pyramidal Neurons, and Both IGFBP2 and 
IGF1 Increased the Density of Mature Spines and 
Total Spines in Dentate Granule Neurons of the 
Hippocampus
IGFBP2 increased the density of mature mushroom spines in 
MPFC layer V pyramidal neuron proximal tufts [F(2, 77) = 3.4, P < 
.05; Fisher’s PLSD posthoc test IGFBP2 vs vehicle] but did not alter 
the density of other spine types or the total number of spines 
in this region (all P >.05) (Figure 5A). IGF1 increased the density 
of mature stubby spines and the total number of spines in the 
inner molecular layer of the dentate gyrus [stubby spines - F(2, 
71) = 3.7, P < .05; Fisher’s PLSD posthoc test IGF1 vs vehicle; total 
spines - F(2, 71) = 3.9, P < .05; Fisher’s PLSD posthoc test IGF1 vs 
vehicle], while the other spine types did not change (all Ps > 0.05) 
(Figure 5B). Lastly, IGFBP2 increased the density of mature stubby 
spines and the total number of spines in the middle molecular 
layer of the dentate gyrus [stubby spines - F(2, 70) = 3.3, P < .05; 
Fisher’s PLSD posthoc test IGFBP2 vs vehicle; total spines - F(2, 
71) = 3.5, P < .05; Fisher’s PLSD posthoc test IGFBP2 vs vehicle], 
while the other spine types did not change (all P > .05) (Figure 5C).
Discussion
The data presented here demonstrate that a single dose of 
IGFBP2 (1 µg/kg i.v.) can induce rapid- and long-lasting effects in 
multiple rat models of PTSD. These effects of IGFBP2 were IGF1 
and AMPA receptor independent. The effects of IGFBP2 may not 
be due to direct interactions with CUS-induced mechanisms 
Figure 4. Insulin-like growth factor binding protein 2 (IGFBP2) produces therapeutic-like effects in a chronic unpredictable stress (CUS) model of posttraumatic stress 
disorder (PTSD). (A) Mean ± SEM immobility time in the Porsolt forced swim test (FS) in naïve (n = 8) and CUS-exposed (n = 8) rats, and CUS-exposed (n = 8) rats that were 
pretreated with IGFBP2. (B) Mean ± SEM sucrose preference (SP) in the sucrose preference test. (C) Mean ± SEM latency to feed in the novelty induced hypophagia (NIH) 
test. (D) Mean ± SEM change in body weight (compared with CUS day 0). (E) Mean ± SEM hedonic 50-kHz ultrasonic vocalizations (USVs) in response to a conditioned 
stimuli that predicts heterospecific play. Mean ± SEM hedonic 50-kHz (F) and aversive 20-kHz (G) USVs. (H) Mean ± SEM running speed to self-administer heterospecific 
play. n = 8/group. *P < .05 Fisher’s PLSD posthoc test vs no-CUS group; #P < .05 Fisher’s PLSD posthoc test vs CUS group.
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leading to pathophysiology, since the same drug effects were 
seen in non-CUS rats (supplemental Figure 2). However, given 
that each of the non-CUS models used in the present studies 
experienced a preexposure stress (iv injection), IGFBP2 may 
reverse the effects of both acute and chronic stress. Both fluox-
etine and ketamine are clinically effective treatments for PTSD 
(Connor et al., 1999; Feder and Murrough, 2015) and in preclini-
cal models can reverse the effects of both acute stress and CUS 
(Cryan et al., 2005; Willner, 2005; Li et al., 2010, 2011). The behav-
ioral effects of IGFBP2 were also associated with increased struc-
tural plasticity as measured by mature dendritic spine density 
in the medial prefrontal cortex and hippocampus. These data 
suggest that the therapeutic effects of IGFBP2 are mediated by a 
novel pharmacological pathway.
Both IGFBP2 and IGF1 show unique rapid-acting and long-
lasting therapeutic-like effects in multiple models of PTSD. SSRIs 
are typically used to treat PTSD but have limited efficacy, require 
3 to 4 weeks of daily dosing to show maximal efficacy, and are 
not as effective in treating anhedonia symptoms (Knutson et al., 
1998; Ipser et  al., 2015). Recently, ketamine has been shown 
to have rapid-acting therapeutic effects in PTSD (Feder and 
Murrough, 2015); however, the addictive and psychotomimetic 
properties of ketamine limits its widespread therapeutic use. 
Exposure therapy is an extinction-based psychotherapy that is 
widely used for the treatment of PTSD (Bisson et al., 2013); how-
ever, the therapeutic effects wane after treatment has termi-
nated (Tarrier and Sommerfield, 2004), thus demonstrating poor 
consolidation. In contrast, the therapeutic-like effects of IGFBP2 
and IGF1 occur as early as 1 hour and last at least 2 weeks after 
a single dose and show efficacy in the learning paradigms, as 
well as in the positive and negative affective symptoms of PTSD. 
Therapeutic doses of IGFBP2 and IGF1 are not associated with 
psychotomimetic side effects such as changes in locomotor 
activity. Lastly, the therapeutic-like effects of IGFBP2 and IGF1 
are maintained during the consolidation period after extinction 
training has ended.
These data suggests that IGFBP2 induces its therapeutic-
like effects in PTSD via a novel mechanism. Although IGFBP2 
is an IGF1 chaperone, it has also been shown to have IGF1-
independent effects via interaction with non-IGF1 binding 
domains (Reyer et al., 2015). The effects of IGF1 are due to acti-
vation of the IGF1 receptor, followed by downstream AMPA 
receptor activation (Burgdorf et al., 2015a). In contrast to IGF1, 
the therapeutic-like effects of IGFBP2 in the Porsolt test were 
not blocked by either an IGF1 or AMPA receptor antagonist. It 
is likely that NBQX or JB1 would not block the effects of IGFBP2 
in fear extinction/consolidation given that the mechanism of 
action of IGFBP2 may be shared across PTSD-related behaviors. 
In addition, IGFBP2 was 100 times more potent than IGF1 in the 
PTSD models used. IGFBP2 is a relatively large circulating pro-
tein (36 kD) with multiple binding domains, and it appears likely 
that the behavioral effects of IGFBP2 are due to interaction with 
a novel target via a non-IGF1 binding domain.
Structural plasticity may underlie the long-lasting effects 
of IGFBP2 and IGF1. Fluoxetine and ketamine have been shown 
to increase mature dendritic spine density in the hippocam-
pus and/or medial prefrontal cortex. While ketamine increases 
immature spines, mature spines, and total number of spines (Li 
et al., 2010, 2011), chronic fluoxetine treatment increases both 
the density and proportion of mature spines without affecting 
total spine number (Ampuero et al., 2010). In contrast, IGFBP2 
and IGF1 show a third pattern of spine alterations: an increase 
in only mature dendritic spines, with a concomitant increase in 
total spine number. The increase in structural plasticity induced 
by IGF1 and ketamine is also associated with an enhancement 
in metaplasticity, that is, a lowered threshold for plastic changes 
in synapse strength, measured as an increased magnitude of 
LTP induced in slices 24 hours postdosing (Burgdorf et al., 2013, 
2015b, 2015c; Graef et al., 2015). In addition, the effects of IGF1 
and IGFBP2 are region dependent and are mainly seen in the 
MPFC, a structure widely implicated in PTSD/anxiety disor-
ders (Shin and Liberzon, 2010). Future studies should examine 
the effect of IGFBP2 on LTP, metaplasticity, and dendritic spine 
dynamics in CUS-treated rats to evaluate the therapeutic poten-
tial of IGFBP2.
The findings reported here suggest that IGFBP2 may have 
therapeutic value for the treatment of PTSD, and that IGFBP2 
produces these effects via a novel mechanism of action. Future 
studies will be needed to determine which binding domain(s) 
of IGFBP2 are responsible for its therapeutic-like effects, and 
the site(s) of action responsible for these effects. In addition, 
other IGFBPs should be examined given that some of them 
have been shown to have protective effects in stress as well as 
hypoxia-ischemia, which could be relevant to PTSD (Guan, 2011; 
Figure 5. Insulin-like growth factor binding protein 2 (IGFBP2) (1 µg/kg i.v.) and insulin-like growth factor I (IGF1) (100 µg/kg i.v.) differentially increased the density 
of mature dendritic spines and total spine density in either the MPFC or hippocampus 24 hours postdosing. In male 2- to 3-month-old rats. (A) IGFBP2 (1 µg/kg i.v.) 
significantly increased the density of mature mushroom spines in MPFC layer V tufts; (B) IGF1 (100 µg/kg i.v) increased the density of mature stubby spines as well as 
total spine density in the primary apical dentate gyrus (100–150 μM from the dendrite). (C) IGFBP2 increased the density of mature stubby spines as well as total spine 
density in the secondary apical dentate gyrus (50 μM from the dendritic branch). Mean ± SEM. n = 17 to 31 cells/group (n = 3–4 rats/group; 716–1333 spines/group), *P < 
.05 Fisher’s PLSD posthoc test vs vehicle.
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Basta-Kaim et  al., 2014). Thus, IGFBP2 and mimetics offer the 
potential for a new generation of therapeutics for PTSD.
Supplementary Material
Supplementary data are available at International Journal of 
Neuropsychopharmacology online.
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